|Day Low/High||130.30 / 133.74|
|52 Wk Low/High||96.42 / 164.76|
As cannabis becomes more and more legal, investors have started to wonder what that means for them.
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?
Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.
The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
Jim Cramer weighs in on DocuSign, DexCom, Skechers USA, Campbell Soup, Evolus, Zscaler, Lockheed Martin and more.
Jim Cramer says there's the market that's about entertainment and anything that delivers entertainment to you. And then there's everything else.
While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.
It's important to know the difference between broken stocks and broken companies.
Jim Cramer shines a spotlight on Snap, Costco, Seagate Technology, GW Pharmaceuticals, Danaher, General Mills and more.
We have a wall of worry to overcome, but it's important to hear the other side of the trade, says Jim Cramer. Take Apple and Facebook, for example.
A string of good news for the cannabis sector may prompt institutional investors to get into the game, but watch valuations increase.
Jim Cramer says analysts and trade woes put a damper on buying ahead of the weekend. So let's get the game plan for next week.
The game plan is to spot the charts that have more room to run.
Jim Cramer takes a closer look at American Electric Power, Fifth Third Bancorp, Applied Materials, EPR Properties, GW Pharmaceuticals and Longfin.
Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.
MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.
Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.
Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.